Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Furosemide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.80 |
| ▸ | CA1 | P00915 | 6/20 | 0.80 |
| ▸ | CA2 | P00918 | 6/20 | 0.80 |
| ▸ | CA9 | Q16790 | 6/20 | 0.80 |
| ▸ | CA6 | P23280 | 5/20 | 0.80 |
| ▸ | CA7 | P43166 | 5/20 | 0.80 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.80 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.80 |
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.80 |
| ▸ | CA5A | P35218 | 4/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.80 |
| ▸ | CA4 | P22748 | 1/20 | 0.80 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.80 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.80 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.80 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.80 |
| ▸ | APP | P05067 | 9/20 | 0.64 |
| ▸ | AQP1 | P29972 | 1/20 | 0.55 |
| ▸ | TEX264 | Q9Y6I9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Furosemide SCHEMBL30369125 | 1.00 | CA12 (0.80) | CA12CA1CA2CA9CA6 | |
| Furosemide SCHEMBL11793416 | 0.98 | CA12 (0.80) | CA12CA1CA2CA9CA6 | |
| Furosemide SCHEMBL3095277 | 0.98 | CA12 (0.80) | CA12CA1CA2CA9CA6 | |
| Furosemide SCHEMBL18729742 | 0.98 | CA12 (0.80) | CA12CA1CA2CA9CA6 | |
| Furosemide SCHEMBL2947473 | 0.98 | CA12 (0.80) | CA12CA1CA2CA9CA6 | |
| SCHEMBL29436027 | 0.90 | CA12 (0.75) | CA12CA1CA2CA9CA6 | |
| SCHEMBL231706 | 0.90 | CA12 (0.75) | CA12CA1CA2CA9CA6 | |
| SCHEMBL229073 | 0.90 | CA12 (0.85) | CA12CA1CA2CA9CA6 | |
| Furosemide SCHEMBL29406913 | 0.89 | CISD1 (1.00) | CA12CA1CA2CA9CA6 | |
| SCHEMBL2880956 | 0.89 | CA12 (0.83) | CA12CA1CA2CA9CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118370312-B | Method for improving freezing tolerance of bovine blastula | 吉林农业大学 | 2024-10-11 | — | — | CN | claimed |
| CN-117510444-B | Refining process of furosemide | 成都瑞尔医药科技有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-117510444-A | Refining process of furosemide | 成都瑞尔医药科技有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-113584177-B | Application of compound refractory multiple myeloma marker | 中南大学 | 2023-04-25 | — | — | CN | claimed |
| CN-113584177-A | Application of marker of relapsing refractory multiple myeloma | 中南大学 | 2021-11-02 | — | — | CN | claimed |
| CN-106117168-A | A kind of preparation method of furosemide | 东北制药集团股份有限公司 | 2016-11-16 | — | — | CN | claimed |
| EP-1020192-B1 | Composition against cellulitis | SCHNEIDER MICHAEL (DE) | 2002-06-19 | — | — | EP | claimed |
| US-20260108471-A1 | METHOD OF COATING DRUG-ION EXCHANGE RESIN COMPLEXES | BRILLIAN PHARMA INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260000636-A1 | PHARMACEUTICAL COMPOSITIONS OF FUROSEMIDE AND USES THEREOF | SQ INNOVATION AG (CH) | 2026-01-01 | — | — | US | disclosed |
| US-12491195-B2 | Concentrated liquid pharmaceutical Formulations of furosemide and methods of administering the same | SCPHARMACEUTICALS INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-12491194-B2 | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same | SCPHARMACEUTICALS INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-12491196-B2 | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same | SCPHARMACEUTICALS INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-12491197-B2 | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same | SCPHARMACEUTICALS INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20030152622-A1 | Formulation of an erodible, gastric retentive oral diuretic | ASSERTIO THERAPEUTICS, INC. | 2003-08-14 | — | — | US | disclosed |
| EP-1226831-A1 | Aqueous pharmaceutical solutions with trisubstituted glycyrrhizic acid salts | Baiocchi, Leandro (IT) | 2002-07-31 | — | — | EP | disclosed |
| US-6280744-B1 | PHARMACEUTICAL COMPOSITION WHICH COMPRISES PHARMACEUTICAL ACTIVE AGENT AND INORGANIC AEROGEL PARTICLES | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-08-28 | — | — | US | disclosed |
| CN-1276246-A | Process for preparing medicines with no or low loxic by-effect on gastrointestinal system | WANG XIAO (CN) | 2000-12-13 | — | — | CN | disclosed |
| CN-1175904-A | Use of inorganic aerogels in pharmacy | HOECHST AG (DE) | 1998-03-11 | — | — | CN | disclosed |
| US-4861786-A | Composition for a stable vein compatible injectable solution of torasemide process for the preparation and method of use | BOEHRINGER MANNHEIM GMBH (DE) | 1989-08-29 | — | — | US | disclosed |
| US-4698361-A | Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same | SCHIENA MICHELE G DI | 1987-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030152622-A1 | Formulation of an erodible, gastric retentive oral diuretic | HSPA5, NSF, REN | CA12 1538/4885CA1 778/4885CA2 1470/4885 |
| US-20260108471-A1 | METHOD OF COATING DRUG-ION EXCHANGE RESIN COMPLEXES | ABCB11, SAMM50, CD63 | CA12 2118/4885CA1 3545/4885CA2 3054/4885 |
| US-12491197-B2 | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same | REN, SLCO4C1, SLC5A1 | CA12 778/4885CA1 1674/4885CA2 295/4885 |
| US-12491195-B2 | Concentrated liquid pharmaceutical Formulations of furosemide and methods of administering the same | REN, SLCO4C1, SLC5A1 | CA12 778/4885CA1 1674/4885CA2 295/4885 |
| US-20260000636-A1 | PHARMACEUTICAL COMPOSITIONS OF FUROSEMIDE AND USES THEREOF | SLC10A1, TNNT2, CFTR | CA12 506/4885CA1 744/4885CA2 314/4885 |
| US-12491194-B2 | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same | REN, SLCO4C1, SLC5A1 | CA12 778/4885CA1 1674/4885CA2 295/4885 |
| US-12491196-B2 | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same | REN, SLCO4C1, SLC5A1 | CA12 778/4885CA1 1674/4885CA2 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.